다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Blood reviews, v.45, 2021년, pp.100695 -
Bansal, Rajat (Division of Hematology) , Reshef, Ran (Division of Hematology)
AI-Helper
Abstract Chimeric antigen receptor (CAR) T cell therapy is currently approved for treatment of refractory B-cell malignancies. Response rates in these diseases are impressive by historical standards, but most patients do not have a durable response and there remains room for improvement. To date, C...
Lancet Oncol Locke 20 1 31 2019 10.1016/S1470-2045(18)30864-7 Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
N Engl J Med Neelapu 377 26 2531 2017 10.1056/NEJMoa1707447 Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
N Engl J Med Schuster 380 1 45 2019 10.1056/NEJMoa1804980 Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
N Engl J Med Maude 378 5 439 2018 10.1056/NEJMoa1709866 Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Front Immunol Kosti 9 1104 2018 10.3389/fimmu.2018.01104 Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors
J Pharmacol Exp Ther Schafer 305 3 1222 2003 10.1124/jpet.102.048496 Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
Science Ito 327 5971 1345 2010 10.1126/science.1177319 Identification of a primary target of thalidomide teratogenicity
Leukemia Lopez-Girona 26 11 2326 2012 10.1038/leu.2012.119 Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
Br J Haematol Gandhi 164 6 811 2014 10.1111/bjh.12708 Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)
Science Lu 343 6168 305 2014 10.1126/science.1244917 The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
J Immunol O’Brien 192 11 5118 2014 10.4049/jimmunol.1301992 Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production
Blood LeBlanc 103 5 1787 2004 10.1182/blood-2003-02-0361 Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
Transplant Proc Kim 48 4 1270 2016 10.1016/j.transproceed.2015.12.088 Role of thalidomide on the expression of OX40, 4-1BB, and GITR in T cell subsets
Immunology Kim 152 4 628 2017 10.1111/imm.12804 Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets
J Clin Invest Ramsay 118 7 2427 2008 Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
Proc Natl Acad Sci U S A Davenport 115 9 E2068 2018 10.1073/pnas.1716266115 Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
Front Immunol Watanabe 9 2486 2018 10.3389/fimmu.2018.02486 Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology
Mol Ther Xiong 26 4 963 2018 10.1016/j.ymthe.2018.01.020 Immunological synapse predicts effectiveness of chimeric antigen receptor cells
Cancer Gene Ther Kuramitsu 22 10 487 2015 10.1038/cgt.2015.47 Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses
Cancer Immunol Res Browning 4 8 698 2016 10.1158/2326-6066.CIR-15-0291 Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells
Oncotarget Loschinski 9 17 13125 2018 10.18632/oncotarget.24442 IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner
Blood Hinrichs 111 11 5326 2008 10.1182/blood-2007-09-113050 IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Blood Sabatino 128 4 519 2016 10.1182/blood-2015-11-683847 Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Cancer Res Singh 71 10 3516 2011 10.1158/0008-5472.CAN-10-3843 Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies
Blood Markley 115 17 3508 2010 10.1182/blood-2009-09-241398 IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice
Blood Li 111 1 229 2008 10.1182/blood-2007-05-089375 IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes
Oncoimmunology Otahal 5 4 2016 10.1080/2162402X.2015.1115940 Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
Clin Cancer Res Wang 24 1 106 2018 10.1158/1078-0432.CCR-17-0344 Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma
Cancer Fouquet 119 20 3680 2013 10.1002/cncr.28274 Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma
Bone Marrow Transplant Fried 54 10 1643 2019 10.1038/s41409-019-0487-3 Early and late hematologic toxicity following CD19 CAR-T cells
Am J Hematol Leleu 91 8 806 2016 10.1002/ajh.24416 An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)
Blood Neelapu 134 Supplement_1 2019 10.1182/blood-2019-126369 A phase 2, open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in patients with refractory large B-cell lymphoma (ZUMA-14)
Blood Lonial 134 Supplement_1 2019 10.1182/blood-2019-124298 Translational and clinical evidence of a differentiated profile for the novel CELMoD, Iberdomide (CC-220)
Clin Cancer Res Rasco 25 1 90 2019 10.1158/1078-0432.CCR-18-1203 A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies
Lupus Sci Med Werth 3 Suppl. 1 A41 2016 CT-07 A phase 2, randomised, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, and tolerability, pharmacokinetics, pharmacodynamics and pharmacogenetics of CC-220 in subjects with systemic lupus erythematosus
Leukemia Bjorklund 34 4 1197 2019 10.1038/s41375-019-0620-8 Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
Blood Lopez-Girona 134 Supplement_1 2019 10.1182/blood-2019-124338 CC-92480 Is a novel cereblon E3 ligase modulator with enhanced tumoricidal and immunomodulatory activity against sensitive and resistant multiple myeloma cells
Sci Transl Med Kalos 3 95 2011 10.1126/scitranslmed.3002842 T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
N Engl J Med Porter 365 8 725 2011 10.1056/NEJMoa1103849 Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
Sci Transl Med Porter 7 303 2015 10.1126/scitranslmed.aac5415 Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
J Clin Oncol Turtle 35 26 3010 2017 10.1200/JCO.2017.72.8519 Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib
Clin Pharmacol Ther Wang 97 5 455 2015 10.1002/cpt.85 Targeting Bruton’s tyrosine kinase with ibrutinib in B-cell malignancies
Br J Haematol Aalipour 163 4 436 2013 10.1111/bjh.12573 Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
Blood Dubovsky 122 15 2539 2013 10.1182/blood-2013-06-507947 Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Cancer Discov Gunderson 6 3 270 2016 10.1158/2159-8290.CD-15-0827 Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer
Oncoimmunology Cubillos-Zapata 5 12 2016 10.1080/2162402X.2016.1242544 Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia
Blood Fraietta 127 9 1117 2016 10.1182/blood-2015-11-679134 Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
J Clin Invest Long 127 8 3052 2017 10.1172/JCI89756 Ibrutinib treatment improves T cell number and function in CLL patients
Biochim Biophys Acta Ten Hacken 1863 3 401 2016 10.1016/j.bbamcr.2015.07.009 Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment
Clin Cancer Res Herman 21 20 4642 2015 10.1158/1078-0432.CCR-15-0781 Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo
Leukemia Herman 28 11 2188 2014 10.1038/leu.2014.122 Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
Leukemia Chen 30 4 833 2016 10.1038/leu.2015.316 BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
Oncotarget Ping 8 24 39218 2017 10.18632/oncotarget.16836 The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
Oncoimmunology Benner 8 11 1659704 2019 10.1080/2162402X.2019.1659704 Evidence for interaction of the NLRP3 inflammasome and Bruton’s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta
Nat Rev Clin Oncol Mantovani 14 7 399 2017 10.1038/nrclinonc.2016.217 Tumour-associated macrophages as treatment targets in oncology
Acta Biomater Qiu 92 184 2019 10.1016/j.actbio.2019.05.030 Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy
Leukemia Kondo 32 4 960 2018 10.1038/leu.2017.304 Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
Blood Norde 120 4 728 2012 10.1182/blood-2012-02-412510 Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention
Br J Haematol Olteanu 153 3 408 2011 10.1111/j.1365-2141.2010.08555.x CD200 expression in plasma cell myeloma
Mol Immunol Rijkers 45 4 1126 2008 10.1016/j.molimm.2007.07.013 The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes
Cytom B Clin Cytom Sandes 86 2 98 2013 10.1002/cytob.21128 CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry
Cancer Res Stumpfova 70 7 2962 2010 10.1158/0008-5472.CAN-09-4380 The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma
Clin Cancer Res Ruella 22 11 2684 2016 10.1158/1078-0432.CCR-15-1527 The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma
JCI Insight Geyer 5 2019 Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
Clin Lymphoma Myeloma Leuk Mock 18 11 755 2018 10.1016/j.clml.2018.07.287 Risk of major bleeding with ibrutinib
J Thromb Haemost Shatzel 15 5 835 2017 10.1111/jth.13651 Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
Blood Gauthier 132 Suppl. 1 2018 Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and/or refractory CLL
J Clin Oncol Gill 35 15_suppl 2017 10.1200/JCO.2017.35.15_suppl.7509 CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL
Science Sharma 348 6230 56 2015 10.1126/science.aaa8172 The future of immune checkpoint therapy
Nat Rev Clin Oncol O’Donnell 16 3 151 2019 10.1038/s41571-018-0142-8 Cancer immunoediting and resistance to T cell-based immunotherapy
Immunotherapy Kourie 9 8 647 2017 10.2217/imt-2017-0029 The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives
J Clin Invest Cherkassky 126 8 3130 2016 10.1172/JCI83092 Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Mol Ther Gargett 24 6 1135 2016 10.1038/mt.2016.63 GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade
Clin Cancer Res John 19 20 5636 2013 10.1158/1078-0432.CCR-13-0458 Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells
Nature Gordon 545 7655 495 2017 10.1038/nature22396 PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Br J Cancer Groth 120 1 16 2019 10.1038/s41416-018-0333-1 Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Oncoimmunology Lu 5 12 2016 10.1080/2162402X.2016.1247135 The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Cell Kortlever 171 6 2017 10.1016/j.cell.2017.11.013 Myc cooperates with Ras by programming inflammation and immune suppression
Cancer Immunol Res Kunkele 3 4 368 2015 10.1158/2326-6066.CIR-14-0200 Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD
Cell. Kleffel 162 6 1242 2015 10.1016/j.cell.2015.08.052 Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth
Biomed Res Int Zheng 2017 1293201 2017 10.1155/2017/1293201 PD-L1 promotes self-renewal and tumorigenicity of malignant melanoma initiating cells
Cancer Res Clark 76 23 6964 2016 10.1158/0008-5472.CAN-16-0258 Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma
Signal Transduct Target Ther Gupta 1 2016 10.1038/sigtrans.2016.30 Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer
Hepatology Li 66 6 1920 2017 10.1002/hep.29360 Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1
Science Hui 355 6332 1428 2017 10.1126/science.aaf1292 T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Cytotherapy Zolov 20 10 1259 2018 10.1016/j.jcyt.2018.07.005 Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells
2019 End of phase 1 results From ZUMA-6: Axicabtagene ciloleucel in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma
Biol Blood Marrow Transplant Jacobson 25 3, Supplement 2019 10.1016/j.bbmt.2018.12.314 End of phase 1 results from Zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma
Blood Chong 130 Suppl. 1 2017 Phase I/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy
Blood Chong 129 8 1039 2017 10.1182/blood-2016-09-738245 PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR
Blood Li 132 Suppl. 1 2018 Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia
Mol Ther Heczey 25 9 2214 2017 10.1016/j.ymthe.2017.05.012 CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma
Front Pharmacol Guo 9 1118 2018 10.3389/fphar.2018.01118 Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma
Clin Cancer Res Li 23 22 6982 2017 10.1158/1078-0432.CCR-17-0867 Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors
Nat Biotechnol Rafiq 36 9 847 2018 10.1038/nbt.4195 Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
J Autoimmun Kumar 95 77 2018 10.1016/j.jaut.2018.08.007 A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
Immunol Rev Cheadle 257 1 91 2014 10.1111/imr.12126 CAR T cells: driving the road from the laboratory to the clinic
Mol Ther Milone 17 8 1453 2009 10.1038/mt.2009.83 Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
Sci Signal Salter 11 544 2018 10.1126/scisignal.aat6753 Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Cancer Cell Sun 37 2 2020 10.1016/j.ccell.2019.12.014 THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells
Nat Med Long 21 6 581 2015 10.1038/nm.3838 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Immunity Kawalekar 44 2 380 2016 10.1016/j.immuni.2016.01.021 Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells
Sci Transl Med Singh 8 320 2016 10.1126/scitranslmed.aad5222 Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
Cancer Immunol Immunother Fisher 61 10 1721 2012 10.1007/s00262-012-1237-1 Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Clin Cancer Res Segal 24 8 1816 2018 10.1158/1078-0432.CCR-17-1922 Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer
Clin Cancer Res Tolcher 23 18 5349 2017 10.1158/1078-0432.CCR-17-1243 Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors
Cancer Res Mardiana 77 6 1296 2017 10.1158/0008-5472.CAN-16-1831 A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells
Blood Reshef 134 Supplement_1 2019 10.1182/blood-2019-123772 ZUMA-11: A phase 1/2 multicenter study of axicabtagene ciloleucel (Axi-Cel) + utomilumab patients with refractory large B cell lymphoma
Trends Pharmacol Sci Melero 29 8 383 2008 10.1016/j.tips.2008.05.005 Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies
J Immunol Akhmetzyanova 196 1 484 2016 10.4049/jimmunol.1403039 CD137 agonist therapy can reprogram regulatory T cells into cytotoxic CD4+ T cells with antitumor activity
Cancer Res Palazon 71 3 801 2011 10.1158/0008-5472.CAN-10-1733 Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes
Onco Targets Ther Li 12 5627 2019 10.2147/OTT.S198567 Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
Blood Xue 134 Supplement_1 2019 10.1182/blood-2019-121486 Checkpoint blockade in combination with CD33 chimeric antigen receptor T cell therapy and hypomethylating agent against acute myeloid leukemia
Mol Oncol Fratta 5 2 164 2011 10.1016/j.molonc.2011.02.001 The biology of cancer testis antigens: putative function, regulation and therapeutic potential
Nature Rosenthal 567 7749 479 2019 10.1038/s41586-019-1032-7 Neoantigen-directed immune escape in lung cancer evolution
Expert Rev Hematol Lindblad 10 8 745 2017 10.1080/17474086.2017.1346470 Immunological effects of hypomethylating agents
Oncotarget Srivastava 7 11 12840 2016 10.18632/oncotarget.7326 Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
Blood Cancer J Gang 4 2014 10.1038/bcj.2014.14 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
PLoS One Siebenkas 12 6 2017 10.1371/journal.pone.0179501 Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
Cancer Res Sigalotti 64 24 9167 2004 10.1158/0008-5472.CAN-04-1442 Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2’-deoxycytidine
Oncotarget Wrangle 4 11 2067 2013 10.18632/oncotarget.1542 Alterations of immune response of non-small cell lung cancer with azacytidine
Leukemia Yang 28 6 1280 2014 10.1038/leu.2013.355 Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Curr Hematol Malig Rep von Keudell 14 5 405 2019 10.1007/s11899-019-00540-w The role of PI3K inhibition in lymphoid malignancies
Nat Rev Immunol Lucas 16 11 702 2016 10.1038/nri.2016.93 PI3Kdelta and primary immunodeficiencies
J Allergy Clin Immunol Elkaim 138 1 2016 10.1016/j.jaci.2016.03.022 Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study
Cancer Res Abu Eid 77 15 4135 2017 10.1158/0008-5472.CAN-16-1925 Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-delta inhibition
Leukemia Zheng 32 5 1157 2018 10.1038/s41375-017-0008-6 PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
Front Immunol Bowers 8 1221 2017 10.3389/fimmu.2017.01221 PI3Kdelta inhibition enhances the antitumor fitness of adoptively transferred CD8(+) T cells
N Engl J Med Raje 380 18 1726 2019 10.1056/NEJMoa1817226 Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma
Blood Berdeja 134 2019 10.1182/blood-2019-126660 Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy
Hematol Oncol Cuneo 37 1 3 2019 10.1002/hon.2540 Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper
J Immunol Chellappa 202 5 1397 2019 10.4049/jimmunol.1701703 The PI3K p110delta isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function
Immunology Lim 157 3 210 2019 10.1111/imm.13082 Phosphoinositide 3-kinase delta is a regulatory T-cell target in cancer immunotherapy
Nat Commun Uehara 8 1 951 2017 10.1038/s41467-017-00982-x Regulation of T cell alloimmunity by PI3Kgamma and PI3Kdelta
Mol Ther Walker 25 9 2189 2017 10.1016/j.ymthe.2017.06.008 Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase
J Immunol Watanabe 194 3 911 2015 10.4049/jimmunol.1402346 Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells
Nat Med Fry 24 1 20 2018 10.1038/nm.4441 CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Sci Transl Med O’Rourke 9 2017 10.1126/scitranslmed.aaa0984 A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Nature Hamieh 568 7750 112 2019 10.1038/s41586-019-1054-1 CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Clin Cancer Res Carpenter 19 8 2048 2013 10.1158/1078-0432.CCR-12-2422 B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma
J Clin Oncol Brudno 36 22 2267 2018 10.1200/JCO.2018.77.8084 T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma
J Clin Invest Cohen 129 6 2210 2019 10.1172/JCI126397 B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Proc Natl Acad Sci U S A Xu 116 19 9543 2019 10.1073/pnas.1819745116 Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Lancet Haematol Yan 6 10 e521 2019 10.1016/S2352-3026(19)30115-2 A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
J Hematol Oncol Zhao 11 1 141 2018 10.1186/s13045-018-0681-6 A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Blood Green 134 Supplement_1 2019 10.1182/blood-2019-129582 Response to Bcma CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase
Blood Pont 134 19 1585 2019 10.1182/blood.2019000050 Gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Nat Commun Laurent 6 2015 10.1038/ncomms8333 gamma-Secretase directly sheds the survival receptor BCMA from plasma cells
Trends Immunol Meinl 39 9 673 2018 10.1016/j.it.2018.07.002 Shedding of BAFF/APRIL receptors controls B cells
Blood Cowan 134 Supplement_1 2019 10.1182/blood-2019-129405 Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma
Front Immunol Kelliher 9 1718 2018 10.3389/fimmu.2018.01718 NOTCH signaling in T-cell-mediated anti-tumor immunity and T-cell-based immunotherapies
Nature Yang 565 7738 192 2019 10.1038/s41586-018-0813-8 Structural basis of Notch recognition by human gamma-secretase
Int J Mol Sci Benmebarek 20 6 2019 10.3390/ijms20061283 Killing mechanisms of chimeric antigen receptor (CAR) T cells
J Immunol Caldwell 171 5 2402 2003 10.4049/jimmunol.171.5.2402 The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases
Immunology Hassin 133 2 190 2011 10.1111/j.1365-2567.2011.03426.x Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable
Immunology Meiraz 128 1 69 2009 10.1111/j.1365-2567.2009.03072.x Switch from perforin-expressing to perforin-deficient CD8(+) T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo
Cancer Res Shanker 69 16 6615 2009 10.1158/0008-5472.CAN-09-0685 Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity
Int J Surg Kumar 3 4 268 2005 10.1016/j.ijsu.2005.05.002 An introduction to death receptors in apoptosis
Transplantation Zimmerer 94 11 1103 2012 10.1097/TP.0b013e318270f3c0 Cytotoxic effector function of CD4-independent, CD8(+) T cells is mediated by TNF-alpha/TNFR
Sci Immunol Kearney 3 23 2018 10.1126/sciimmunol.aar3451 Tumor immune evasion arises through loss of TNF sensitivity
Blood Dufva 135 9 597 2019 10.1182/blood.2019002121 Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity
Cancer Cell Petersen 12 5 445 2007 10.1016/j.ccr.2007.08.029 Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis
Cell Varfolomeev 131 4 669 2007 10.1016/j.cell.2007.10.030 IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis
Cell Vince 131 4 682 2007 10.1016/j.cell.2007.10.037 IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis
Pharmacol Ther Bai 144 1 82 2014 10.1016/j.pharmthera.2014.05.007 Small-molecule SMAC mimetics as new cancer therapeutics
Cancer Immunol Res Michie 7 2 183 2019 10.1158/2326-6066.CIR-18-0428 Antagonism of IAPs enhances CAR T-cell efficacy
Cell Death Differ Kearney 24 10 1705 2017 10.1038/cdd.2017.94 PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF
J Clin Invest Zhang 118 4 1398 2008 10.1172/JCI33522 IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers
Curr Opin Immunol Chen 51 103 2018 10.1016/j.coi.2018.03.002 Driving CARs on the uneven road of antigen heterogeneity in solid tumors
J Clin Oncol Infante 32 28 3103 2014 10.1200/JCO.2013.52.3993 Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors
Cell Rep Gomes-Silva 21 1 17 2017 10.1016/j.celrep.2017.09.015 Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent
J Clin Invest Yamamoto 129 4 1551 2019 10.1172/JCI121491 T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Cancer Manag Res Krendyukov 11 8095 2019 10.2147/CMAR.S216675 Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
Blood He 134 Supplement_1 2019 10.1182/blood-2019-122833 Blockade of CD95/CD95L death signaling enhances CAR T cell persistence and antitumor efficacy
Cancer Discov Singh 10 4 552 2020 10.1158/2159-8290.CD-19-0813 Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction
Nat Commun Cruz 7 13895 2016 10.1038/ncomms13895 Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction
Cell Fisher 81 6 935 1995 10.1016/0092-8674(95)90013-6 Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
Science Rieux-Laucat 268 5215 1347 1995 10.1126/science.7539157 Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
Annu Rev Immunol Ma 24 657 2006 10.1146/annurev.immunol.24.021605.090727 Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis
Cancer Immunol Res Alizadeh 7 5 759 2019 10.1158/2326-6066.CIR-18-0466 IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype
Proc Natl Acad Sci U S A Hurton 113 48 E7788 2016 10.1073/pnas.1610544113 Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
Blood Chou 134 2019 10.1182/blood-2019-125960 Combination of NKTR-255, a polymer conjugated human IL-15, with CD19 CAR T Cell immunotherapy in a preclinical lymphoma model
Cancer Immunol Res Rhode 4 1 49 2016 10.1158/2326-6066.CIR-15-0093-T Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models
J Clin Oncol Conlon 33 1 74 2015 10.1200/JCO.2014.57.3329 Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer
Eur Urol Gorchakov 77 3 299 2020 10.1016/j.eururo.2019.08.014 Challenges and prospects of chimeric antigen receptor T-cell therapy for metastatic prostate cancer
Cancer Immunol Immunother Burga 64 7 817 2015 10.1007/s00262-015-1692-6 Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T
Cancer Immunol Res Long 4 10 869 2016 10.1158/2326-6066.CIR-15-0230 Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas
Int Immunopharmacol Tobin 63 282 2018 10.1016/j.intimp.2018.08.007 Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
EBioMedicine Fultang 47 235 2019 10.1016/j.ebiom.2019.08.025 MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
JCI Insight Sun 4 7 2019 10.1172/jci.insight.126853 Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Cell Tavazoie 172 4 2018 10.1016/j.cell.2017.12.026 LXR/ApoE activation restricts innate immune suppression in cancer
Biol Blood Marrow Transplant Sakemura 25 3, Supplement 2019 10.1016/j.bbmt.2018.12.465 Axl-RTK inhibition modulates T cell functions and synergizes with chimeric antigen receptor T cell therapy in B cell malignancies
Int J Mol Sci Yoo 20 10 2019 10.3390/ijms20102469 Tumor-specific reactive oxygen species accelerators improve chimeric antigen receptor T cell therapy in B cell malignancies
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.